Yüksel Ürün/X
Apr 30, 2025, 09:09
Yüksel Ürün: New era for HER2-mutant lung cancer!
Yüksel Ürün, Medical Oncology professor at Ankara University School of Medicine, shared on X:
“New era for HER2-mutant lung cancer!
Zongertinib delivered a 71% response rate, 12.4 months median PFS, and low-grade toxicity. No ILD reported.
Precision hitting its mark!”
Zongertinib in Previously Treated HER2-Mutant Non–Small-Cell Lung Cancer
Authors: John V. Heymach et al.
Read Also: New Paper Alert: Zongertinib in Previously Treated HER2-Mutant NSCLC. Beamion LUNG-1 Study Results
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
May 23, 2025, 17:25
May 23, 2025, 16:24
May 23, 2025, 15:36
May 23, 2025, 13:44